Market Overview

Science Exchange Collaborates with AUM BioTech to Fast-Track Global Drug Discovery by Offering Self-Delivering RNA Silencing FANA ASO Technology for Genetic Research

Share:

Science Exchange, the leading marketplace for outsourced R&D™,
announces a collaboration with AUM
BioTech
, an emerging Philadelphia-based startup, to advance genetic
research and significantly cut short drug discovery and development
time. Science Exchange will now offer AUM BioTech's self-delivering,
next-generation RNA silencing products and alternatives to conventional
CRISPR, siRNA and shRNA approaches.

As a part of this alliance, Science Exchange users will get instant
access to AUM BioTech's 300,000-plus customized and cutting-edge RNA
silencing products targeting thousands of genetic targets powered by
proprietary FANA technology, a technology platform composed of antisense
oligonucleotide (AON) chemistries. These products can be used to target
messenger RNA (mRNA), microRNA (miRNA) and long non-coding (lncRNA) for
a broad spectrum of genetic studies. They can also be used to target
viral, fungal and bacterial RNA. AUM BioTech's FANA antisense
oligonucleotides (FANA ASOs) can be self-delivered both in in vitro
and in vivo models without the use of any conjugates, carriers or
formulations and can be used for basic and translational research. Such
products will significantly benefit the biomedical scientific community
working on difficult-to-transfect primary cells, including, but not
limited to B-Cells, T-cells, macrophages, neuronal cells and primary
cells from diseased donors. It is also important to mention that
researchers working with animal models can use FANAs for their
preclinical studies via multiple routes of administration.

"With FANA, our goal is to shorten the drug discovery and development
time and help bring clinical compounds to market much faster," said
Veenu Aishwarya, founder and CEO of AUM BioTech. "This strategic
alliance with Science Exchange will grant its users on-demand access to
our FANA technology and help them reduce the time and effort needed to
understand the function of genes and their link to diseases."

"AUM BioTech is an innovative company that has developed revolutionary
genetic research products to significantly advance biomedical R&D and
fast-track drug discovery, leading to more effective therapeutic
development," said Elizabeth Iorns, Ph.D., co-founder and CEO of Science
Exchange. "We are thrilled to collaborate with AUM BioTech and further
advance our shared goal to help the global scientific community find
cures for diseases."

About Science Exchange

Science Exchange is the world's leading marketplace for outsourced
R&D™
, providing large R&D organizations with the fastest path
from discovery through development and commercialization. Science
Exchange includes an efficient source-to-secure platform for ordering
6,000+ services from a network of more than 2,500 qualified outsourced
research providers, all with pre-established contracts in place that
protect client intellectual property and confidentiality. The platform
increases access to innovation and improves productivity, freeing
scientists from administrative tasks and delays associated with
sourcing, establishing and managing service provider contracts.
Additionally, the Science Exchange enterprise program enables large R&D
organizations to consolidate research outsourcing spend into a single
strategic relationship, driving efficiency, improving transparency and
oversight, and delivering cost savings. Since being founded in 2011,
Science Exchange has raised more than $58 million from Norwest Venture
Partners, Maverick Capital Ventures, Union Square Ventures,
Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and
others. For more information, visit www.ScienceExchange.com.
Follow the company on Twitter @ScienceExchange,
Facebook
and LinkedIn.

About AUM BioTech

AUM BioTech is a biotechnology company that offers solutions and
products for genetic research using next-generation RNA silencing
technology in diverse life science verticals including biomedical
research, medicine, and agriculture. AUM's next generation FANA
Antisense Oligonucleotide (FANA ASO) technology is globally being used
by biomedical scientists and researchers working on basic, transitional
and preclinical research. FANA ASO technology can be used to silence or
regulate RNA modalities such as – mRNA, microRNA and long non-coding
RNA. AUM's next generation FANA technology provides alternatives to
CRISPR, siRNA and shRNA approaches. FANA oligos are self-deliverable and
do not need any transfection reagents or delivery agents and can work
both in in vitro and in vivo models. AUM's FANA ASO
technology also provides next-generation solutions for genetic research
in agriculture and entomology. AUM BioTech is headquartered in
Philadelphia, Pennsylvania, USA. Follow the company on Twitter @aumbiotech,
LinkedIn,
and Facebook.

View Comments and Join the Discussion!